Pharmacological interventions for spinal cord injury: Where do we stand? How might we step forward?

Research output: Contribution to journalReview articlepeer-review

81 Scopus citations


Despite numerous studies reporting some measures of efficacy in the animal literature, there are currently no effective therapies for the treatment of traumatic spinal cord injuries (SCI) in humans. The purpose of this review is to delineate key pathophysiological processes that contribute to neurological deficits after SCI, as well as to describe examples of pharmacological approaches that are currently being tested in clinical trials, or nearing clinical translation, for the therapeutic management of SCI. In particular, we will describe the mechanistic rationale to promote neuroprotection and/or functional recovery based on theoretical, yet targeted pathological events. Finally, we will consider the clinical relevancy for emerging evidence that pharmacologically targeting mitochondrial dysfunction following injury may hold the greatest potential for increasing tissue sparing and, consequently, the extent of functional recovery following traumatic SCI.

Original languageEnglish
Pages (from-to)15-29
Number of pages15
JournalPharmacology and Therapeutics
Issue number1
StatePublished - Oct 2011


  • Clinical trials
  • Erythropoietin
  • Fampridine
  • Minocycline
  • Mitochondria
  • Riluzole

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Pharmacological interventions for spinal cord injury: Where do we stand? How might we step forward?'. Together they form a unique fingerprint.

Cite this